Erenumab
Erenumab
Erenumab (pronounced as eh-REH-noo-mab) is a monoclonal antibody medication used for the preventive treatment of migraine in adults. It is marketed under the brand name Aimovig and is the first in a class of drugs that block the activity of a molecule known as the calcitonin gene-related peptide (CGRP), which is involved in migraine attacks.
Etymology
The name Erenumab is derived from the International Nonproprietary Names (INN), where "Ere" refers to the target (CGRP receptor), "nu" indicates it is a human antibody, and "mab" is the suffix for monoclonal antibodies.
Mechanism of Action
Erenumab works by blocking the CGRP receptor, thus preventing the binding of CGRP and inhibiting its function. CGRP is a neuropeptide that plays a crucial role in the pathophysiology of migraines. By blocking its receptor, Erenumab prevents the transmission of pain signals in the brain.
Related Terms
- Monoclonal antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells.
- Migraine: A type of headache characterized by recurrent attacks of severe pain, usually on one side of the head, often accompanied by nausea, vomiting, and sensitivity to light or sound.
- Calcitonin Gene-Related Peptide (CGRP): A neuropeptide that plays a key role in the transmission of pain signals in the brain.
- Neuropeptide: Small protein-like molecules used by neurons to communicate with each other.
See Also
External links
- Medical encyclopedia article on Erenumab
- Wikipedia's article - Erenumab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski